INBX · Inhibrx Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $1.30M | $0 | - | $0 | $100.0K |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| R&D | $25.22M | - | $28.54M | $22.27M | $63.85M | - | $38.06M | $34.11M |
| SG&A | $5.71M | - | $5.28M | $6.42M | $9.97M | - | $7.90M | $7.26M |
| Total Operating Expenses | $30.93M | - | $33.81M | $28.69M | $73.83M | - | $45.95M | $41.37M |
| D&A | $537.0K | - | $582.0K | $662.0K | $360.0K | - | $304.0K | $295.0K |
| Operating Income | ($30.93M) | - | ($33.81M) | ($27.39M) | ($73.83M) | - | ($46.80M) | ($41.34M) |
| Interest Expense | $3.51M | - | $3.18M | $3.14M | $8.13M | - | $0 | $7.91M |
| Income Tax | $0 | - | $0 | $2.0K | $0 | - | $0 | $2.0K |
| Net Income | ($33.44M) | - | ($35.26M) | ($28.65M) | ($43.31M) | - | ($43.86M) | ($78.71M) |
| EPS - Basic | ($2.15) | - | ($2.28) | ($1.85) | ($5.77) | - | ($2.84) | ($4.31) |
| EPS - Diluted | ($2.15) | - | ($2.28) | ($1.85) | ($5.77) | - | ($2.84) | ($4.31) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $161.66M | $124.22M | $153.09M | $186.57M | $216.52M | $152.60M | $196.33M | $226.86M |
| Accounts Receivable | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - |
| Accounts Payable | $8.76M | $5.94M | $6.77M | $8.29M | $8.89M | $9.24M | $12.37M | $10.95M |
| Current Assets | $171.34M | $132.83M | $161.42M | $193.96M | $223.39M | $160.40M | $207.45M | $242.06M |
| Total Assets | $183.97M | $146.48M | $177.47M | $212.12M | $242.64M | $180.77M | $222.56M | $307.89M |
| Current Liabilities | $26.51M | $33.80M | $35.98M | $38.94M | $43.64M | $40.73M | $44.09M | $39.05M |
| Long-term Debt | $174.99M | $100.56M | $99.92M | $99.28M | $98.65M | $0 | $0 | $0 |
| Total Liabilities | $205.00M | $138.49M | $140.64M | $143.56M | $148.20M | $47.18M | $44.09M | $264.39M |
| Stockholders' Equity | ($21.04M) | $7.99M | $36.83M | $68.56M | $94.44M | $133.58M | $129.59M | ($24.81M) |
| Retained Earnings | ($279.63M) | ($246.19M) | ($213.35M) | ($178.10M) | ($149.44M) | ($106.13M) | ($58.27M) | ($14.40M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($38.03M) | - | - | - | ($63.05M) | - | - | - |
| Investing Cash Flow | $0 | - | - | - | ($1.12M) | - | - | - |
| Financing Cash Flow | $75.46M | - | - | - | $38.73M | - | - | - |
| CapEx | $0 | - | - | - | $1.12M | - | - | - |
| Free Cash Flow | ($38.03M) | - | - | - | ($64.17M) | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | -2106.8% | - | - | - | -41339.0% |
| EBITDA margin | - | - | - | -2055.9% | - | - | - | -41044.0% |
| Net margin | - | - | - | -2204.2% | - | - | - | -78710.0% |
| Free cash flow margin | - | - | - | - | - | - | - | - |
| FCF / Net income | 1.14 | - | - | - | 1.48 | - | - | - |
| R&D / Revenue | - | - | - | 1712.8% | - | - | - | 34106.0% |
| SG&A / Revenue | - | - | - | 494.0% | - | - | - | 7263.0% |
| Effective tax rate | - | - | - | - | - | - | - | - |
| Return on assets | -18.2% | - | -19.9% | -13.5% | -17.8% | - | -19.7% | -25.6% |
| Return on equity | 159.0% | - | -95.7% | -41.8% | -45.9% | - | -33.8% | 317.2% |
| Return on invested capital | -15.9% | - | -19.5% | -12.9% | -30.2% | - | -28.5% | - |
| Liquidity | ||||||||
| Current ratio | 6.46 | 3.93 | 4.49 | 4.98 | 5.12 | 3.94 | 4.70 | 6.20 |
| Quick ratio | 6.46 | 3.93 | 4.49 | 4.98 | 5.12 | 3.94 | 4.70 | 6.20 |
| Cash ratio | 6.10 | 3.68 | 4.25 | 4.79 | 4.96 | 3.75 | 4.45 | 5.81 |
| Leverage | ||||||||
| Debt / Equity | -8.32 | 12.58 | 2.71 | 1.45 | 1.04 | 0.00 | 0.00 | 0.00 |
| Debt / Assets | 0.95 | 0.69 | 0.56 | 0.47 | 0.41 | 0.00 | 0.00 | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest coverage | -8.8x | - | -10.6x | -8.7x | -9.1x | - | - | -5.2x |
| Equity multiplier | -8.75 | 18.33 | 4.82 | 3.09 | 2.57 | 1.35 | 1.72 | -12.41 |
| Liabilities / Assets | 1.11 | 0.95 | 0.79 | 0.68 | 0.61 | 0.26 | 0.20 | 0.86 |
| Efficiency | ||||||||
| Asset turnover | - | - | 0.00 | 0.01 | 0.00 | - | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - |
| Valuation | ||||||||
| P / E | - | - | - | - | - | - | - | - |
| P / B | - | - | 14.2x | 3.2x | 2.0x | - | 1.9x | - |
| P / S | - | - | - | 169.8x | - | - | - | 1546.1x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | - | - | - | 1200.0% | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 58.1% | - | 27.7% | 33.7% | - | - | - | - |
| Net income growth (YoY) | 22.8% | - | 19.6% | 63.6% | - | - | - | - |
| EPS growth (YoY) | 62.7% | - | 19.7% | 57.1% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 40.7% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -94.0% | -71.6% | - | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.30M totalReportable Segment$1.30M · 100.0%
Product / service
$2.60M totalLicense Non Affiliate$1.30M · 50.0%
License$1.30M · 50.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Inhibrx Biosciences against the 5 most active filers in the same SIC group.